Combined foscarnet -Ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct)

A. Bacigalupo, S. Bregante, E. Tedone, A. Isaza, M. T. Van Lint, F. Moro, G. Trespi, D. Occhini, F. Gualandi, T. Lamparelli, A. M. Marmont

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Thirty two allogeneic bone marrow transplant (BMT) recipients, aged 16-55 (median 35), with CMV antigenemia (=>5 positive cells) developing at a median interval from BMT of 49 days, were given combined treatment with foscarnet and gancyclovir for 15 days. Maintenance was given with foscarnet and ganciclovir on alternate days for an additional 2 weeks. 31/32 patients were on cyclosporin 30 on systemic antibiotics and 9 were on intravenous amphotericin Median laboratory values on day 1 and 15 of treatment were respectevely creatinine 1.0-1.1 mg%; WBC 5.7-4.1 x 109/l; platelets 78 72 x 109/l. All patients cleared CMV-antigenemia by day +15, though 5 reactivated on and 14 off maintenance: the dose of foscarnet (but not ganciclovir) received in the first 15 days was significantly lower in patients reactivating within 30 days (p = 0.0002). Six patients died, one with IP, one with multiorgan failure, and four with infections. Eighteen patients survive 119-1051 days pest-transplant. The actuarial TRM at 1 year is 23%. This study shows that combined foscarnet-ganciclovir is one therapeutic option allogeneic BMT recipients developing CMVAg-emia with a high number of CMVAg+ cells: treatment can be given together with cyclosporin and antibiotics with appropriate dose reductions; it produces prompt clearing of CMV infection, and may reduce transplant related mortality when compared to single agent therapy.

Original languageEnglish
Pages (from-to)110-114
Number of pages5
JournalBone Marrow Transplantation
Volume18
Issue numberSUPPL. 2
Publication statusPublished - Nov 1996

Fingerprint

Foscarnet
Ganciclovir
Cytomegalovirus Infections
Stem Cell Transplantation
Bone Marrow
Transplants
Cyclosporine
Maintenance
Anti-Bacterial Agents
Therapeutics
Amphotericin B
Infection
Creatinine
Blood Platelets
Cell Count
Mortality

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Combined foscarnet -Ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct). / Bacigalupo, A.; Bregante, S.; Tedone, E.; Isaza, A.; Van Lint, M. T.; Moro, F.; Trespi, G.; Occhini, D.; Gualandi, F.; Lamparelli, T.; Marmont, A. M.

In: Bone Marrow Transplantation, Vol. 18, No. SUPPL. 2, 11.1996, p. 110-114.

Research output: Contribution to journalArticle

@article{c38ed8f208794b3ca37da54d0fa8a989,
title = "Combined foscarnet -Ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct)",
abstract = "Thirty two allogeneic bone marrow transplant (BMT) recipients, aged 16-55 (median 35), with CMV antigenemia (=>5 positive cells) developing at a median interval from BMT of 49 days, were given combined treatment with foscarnet and gancyclovir for 15 days. Maintenance was given with foscarnet and ganciclovir on alternate days for an additional 2 weeks. 31/32 patients were on cyclosporin 30 on systemic antibiotics and 9 were on intravenous amphotericin Median laboratory values on day 1 and 15 of treatment were respectevely creatinine 1.0-1.1 mg{\%}; WBC 5.7-4.1 x 109/l; platelets 78 72 x 109/l. All patients cleared CMV-antigenemia by day +15, though 5 reactivated on and 14 off maintenance: the dose of foscarnet (but not ganciclovir) received in the first 15 days was significantly lower in patients reactivating within 30 days (p = 0.0002). Six patients died, one with IP, one with multiorgan failure, and four with infections. Eighteen patients survive 119-1051 days pest-transplant. The actuarial TRM at 1 year is 23{\%}. This study shows that combined foscarnet-ganciclovir is one therapeutic option allogeneic BMT recipients developing CMVAg-emia with a high number of CMVAg+ cells: treatment can be given together with cyclosporin and antibiotics with appropriate dose reductions; it produces prompt clearing of CMV infection, and may reduce transplant related mortality when compared to single agent therapy.",
author = "A. Bacigalupo and S. Bregante and E. Tedone and A. Isaza and {Van Lint}, {M. T.} and F. Moro and G. Trespi and D. Occhini and F. Gualandi and T. Lamparelli and Marmont, {A. M.}",
year = "1996",
month = "11",
language = "English",
volume = "18",
pages = "110--114",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Combined foscarnet -Ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct)

AU - Bacigalupo, A.

AU - Bregante, S.

AU - Tedone, E.

AU - Isaza, A.

AU - Van Lint, M. T.

AU - Moro, F.

AU - Trespi, G.

AU - Occhini, D.

AU - Gualandi, F.

AU - Lamparelli, T.

AU - Marmont, A. M.

PY - 1996/11

Y1 - 1996/11

N2 - Thirty two allogeneic bone marrow transplant (BMT) recipients, aged 16-55 (median 35), with CMV antigenemia (=>5 positive cells) developing at a median interval from BMT of 49 days, were given combined treatment with foscarnet and gancyclovir for 15 days. Maintenance was given with foscarnet and ganciclovir on alternate days for an additional 2 weeks. 31/32 patients were on cyclosporin 30 on systemic antibiotics and 9 were on intravenous amphotericin Median laboratory values on day 1 and 15 of treatment were respectevely creatinine 1.0-1.1 mg%; WBC 5.7-4.1 x 109/l; platelets 78 72 x 109/l. All patients cleared CMV-antigenemia by day +15, though 5 reactivated on and 14 off maintenance: the dose of foscarnet (but not ganciclovir) received in the first 15 days was significantly lower in patients reactivating within 30 days (p = 0.0002). Six patients died, one with IP, one with multiorgan failure, and four with infections. Eighteen patients survive 119-1051 days pest-transplant. The actuarial TRM at 1 year is 23%. This study shows that combined foscarnet-ganciclovir is one therapeutic option allogeneic BMT recipients developing CMVAg-emia with a high number of CMVAg+ cells: treatment can be given together with cyclosporin and antibiotics with appropriate dose reductions; it produces prompt clearing of CMV infection, and may reduce transplant related mortality when compared to single agent therapy.

AB - Thirty two allogeneic bone marrow transplant (BMT) recipients, aged 16-55 (median 35), with CMV antigenemia (=>5 positive cells) developing at a median interval from BMT of 49 days, were given combined treatment with foscarnet and gancyclovir for 15 days. Maintenance was given with foscarnet and ganciclovir on alternate days for an additional 2 weeks. 31/32 patients were on cyclosporin 30 on systemic antibiotics and 9 were on intravenous amphotericin Median laboratory values on day 1 and 15 of treatment were respectevely creatinine 1.0-1.1 mg%; WBC 5.7-4.1 x 109/l; platelets 78 72 x 109/l. All patients cleared CMV-antigenemia by day +15, though 5 reactivated on and 14 off maintenance: the dose of foscarnet (but not ganciclovir) received in the first 15 days was significantly lower in patients reactivating within 30 days (p = 0.0002). Six patients died, one with IP, one with multiorgan failure, and four with infections. Eighteen patients survive 119-1051 days pest-transplant. The actuarial TRM at 1 year is 23%. This study shows that combined foscarnet-ganciclovir is one therapeutic option allogeneic BMT recipients developing CMVAg-emia with a high number of CMVAg+ cells: treatment can be given together with cyclosporin and antibiotics with appropriate dose reductions; it produces prompt clearing of CMV infection, and may reduce transplant related mortality when compared to single agent therapy.

UR - http://www.scopus.com/inward/record.url?scp=10544220428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10544220428&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 110

EP - 114

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - SUPPL. 2

ER -